Symbols / SPRY
SPRY Chart
About
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions. The company is involved in the development of neffy, a needle-free and low-dose intranasal epinephrine nasal spray for rescue medication for people with Type I severe allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. The company was founded in 2015 and is headquartered in San Diego, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 906.44M |
| Enterprise Value | 1.69B | Income | -80.04M | Sales | 142.77M |
| Book/sh | 1.49 | Cash/sh | 1.46 | Dividend Yield | — |
| Payout | 0.00% | Employees | 162 | IPO | — |
| P/E | — | Forward P/E | -6.23 | PEG | — |
| P/S | 6.35 | P/B | 6.14 | P/C | — |
| EV/EBITDA | -18.80 | EV/Sales | 11.83 | Quick Ratio | 6.41 |
| Current Ratio | 6.66 | Debt/Eq | 115.00 | LT Debt/Eq | — |
| EPS (ttm) | -0.81 | EPS next Y | -1.47 | EPS Growth | — |
| Revenue Growth | 14.72% | Earnings | 2026-03-09 | ROA | -19.22% |
| ROE | -45.92% | ROIC | — | Gross Margin | 80.46% |
| Oper. Margin | -163.66% | Profit Margin | -56.06% | Shs Outstand | 98.85M |
| Shs Float | 93.01M | Short Float | 35.27% | Short Ratio | 12.05 |
| Short Interest | — | 52W High | 18.90 | 52W Low | 6.66 |
| Beta | 0.74 | Avg Volume | 1.61M | Volume | 308.27K |
| Target Price | $28.83 | Recom | None | Prev Close | $9.14 |
| Price | $9.17 | Change | 0.33% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$28.83
Mean price target
2. Current target
$9.17
Latest analyst target
3. DCF / Fair value
$-10.23
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$9.17
Low
$12.00
High
$39.00
Mean
$28.83
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-09-04 | init | Roth Capital | — → Buy | $40 |
| 2025-03-07 | init | Scotiabank | — → Sector Outperform | $30 |
| 2025-01-14 | main | Raymond James | Strong Buy → Strong Buy | $28 |
| 2025-01-13 | main | Leerink Partners | Outperform → Outperform | $27 |
| 2024-10-08 | reit | Cantor Fitzgerald | Overweight → Overweight | $30 |
| 2024-09-20 | main | Leerink Partners | Outperform → Outperform | $25 |
| 2024-09-16 | reit | Cantor Fitzgerald | Overweight → Overweight | $30 |
| 2024-09-09 | reit | Cantor Fitzgerald | Overweight → Overweight | $30 |
| 2024-08-20 | init | Cantor Fitzgerald | — → Overweight | $30 |
| 2024-08-13 | up | Raymond James | Outperform → Strong Buy | $22 |
| 2024-07-25 | init | Raymond James | — → Outperform | $18 |
| 2024-03-11 | reit | Wedbush | Outperform → Outperform | $19 |
| 2024-03-05 | up | Leerink Partners | Market Perform → Outperform | $18 |
| 2023-11-13 | main | Wedbush | Outperform → Outperform | $13 |
| 2023-09-21 | main | Wedbush | Outperform → Outperform | $5 |
| 2023-09-20 | down | William Blair | Outperform → Market Perform | — |
| 2023-08-14 | reit | Wedbush | Outperform → Outperform | $15 |
| 2023-06-21 | main | Wedbush | Outperform → Outperform | $15 |
| 2023-05-18 | reit | Wedbush | Outperform → Outperform | $17 |
| 2023-05-12 | reit | Wedbush | Outperform → Outperform | $17 |
- ARS Pharmaceuticals, Inc. (SPRY) Stock Analysis: Exploring A 213% Potential Upside - DirectorsTalk Interviews Wed, 25 Feb 2026 04
- Assessing ARS Pharmaceuticals (SPRY) Valuation After A 19.3% Single Day Share Price Jump - Yahoo Finance Sat, 10 Jan 2026 08
- ARS Pharmaceuticals: Climbing Neffy Sales And Global Expansion Could Re-Rate The Stock - Seeking Alpha Fri, 13 Feb 2026 08
- Needle-free allergy rescue for kids wins key EU support - Stock Titan Mon, 02 Feb 2026 08
- $SPRY stock is up 14% today. Here's what we see in our data. | SPRY Stock News - Quiver Quantitative Fri, 09 Jan 2026 08
- How Ars Pharmaceuticals Inc. (SPRY) Affects Rotational Strategy Timing - Stock Traders Daily Wed, 18 Feb 2026 00
- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock Catapults 25% Though Its Price And Business Still Lag The Industry - simplywall.st Sat, 10 Jan 2026 08
- With ARS Pharmaceuticals Stock Surging, Have You Considered The Downside? - Trefis Sun, 21 Dec 2025 08
- ARS Pharmaceuticals (SPRY) Is Up 5.2% After Securing $250M Term Loan to Accelerate Neffy Launch – Has the Bull Case Changed? - Yahoo Finance Sat, 04 Oct 2025 07
- SPRY - ARS Pharms Latest Stock News & Market Updates - Stock Titan ue, 04 Nov 2025 08
- ARS Pharmaceuticals, Inc. (SPRY) Stock Analysis: A Biotech Player with a Promising 213% Upside Potential - DirectorsTalk Interviews ue, 21 Oct 2025 07
- ARS Pharmaceuticals (NASDAQ:SPRY) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway - simplywall.st Fri, 15 Aug 2025 07
- Needle-free epinephrine nasal spray may cut costs and boost patient preference - Stock Titan ue, 10 Feb 2026 08
- ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Beats Revenue Estimates - Yahoo Finance Mon, 10 Nov 2025 08
- Insider Sale: Chief Operating Officer of $SPRY Sells 21,828 Shares | SPRY Stock News - Quiver Quantitative Fri, 14 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 21828 | 13970 | — | Conversion of Exercise of derivative security at price 0.64 per share. | DORSEY BRIAN T | Chief Operating Officer | — | 2025-11-13 00:00:00 | D |
| 1 | 21828 | 190050 | — | Sale at price 8.71 per share. | DORSEY BRIAN T | Chief Operating Officer | — | 2025-11-13 00:00:00 | D |
| 2 | 30000 | 25200 | — | Conversion of Exercise of derivative security at price 0.84 per share. | CHAKMA JUSTIN | Officer | — | 2025-11-12 00:00:00 | D |
| 3 | 166380 | 1476147 | — | Sale at price 8.86 - 8.91 per share. | CHAKMA JUSTIN | Officer | — | 2025-11-12 00:00:00 | D |
| 4 | 350000 | — | — | Stock Gift at price 0.00 per share. | SHAH PRATIK | Director | — | 2025-11-12 00:00:00 | I |
| 5 | 12500 | 18750 | — | Conversion of Exercise of derivative security at price 1.50 per share. | SCOTT KATHLEEN D | Chief Financial Officer | — | 2025-08-21 00:00:00 | D |
| 6 | 50000 | 724345 | — | Sale at price 14.49 per share. | LOWENTHAL RICHARD E | Chief Executive Officer | — | 2025-08-21 00:00:00 | I |
| 7 | 12500 | 187500 | — | Sale at price 15.00 per share. | SCOTT KATHLEEN D | Chief Financial Officer | — | 2025-08-21 00:00:00 | D |
| 8 | 50000 | 703755 | — | Sale at price 14.03 - 14.09 per share. | TANIMOTO SARINA | Officer and Beneficial Owner of more than 10% of a Class of Security | — | 2025-08-20 00:00:00 | I |
| 9 | 15000 | 22500 | — | Conversion of Exercise of derivative security at price 1.50 per share. | KARAS ERIC | Officer | — | 2025-07-01 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.03 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -3.08M | -67.52M | -35.06M | -19.24M |
| TotalUnusualItems | -140.00K | |||
| TotalUnusualItemsExcludingGoodwill | -140.00K | |||
| NetIncomeFromContinuingOperationNetMinorityInterest | 8.00M | -54.37M | -34.68M | -20.24M |
| ReconciledDepreciation | -7.17M | -6.78M | 319.00K | 213.00K |
| ReconciledCostOfRevenue | 977.00K | 0.00 | ||
| EBITDA | -3.08M | -67.52M | -35.20M | -19.24M |
| EBIT | -3.08M | -67.52M | -35.52M | -19.45M |
| NormalizedIncome | 8.00M | -54.37M | -34.54M | -20.24M |
| NetIncomeFromContinuingAndDiscontinuedOperation | 8.00M | -54.37M | -34.68M | -20.24M |
| TotalExpenses | 92.23M | 67.55M | 36.83M | 24.96M |
| TotalOperatingIncomeAsReported | -3.08M | -67.52M | -35.52M | -19.45M |
| DilutedAverageShares | 102.39M | 95.22M | 39.96M | 93.77M |
| BasicAverageShares | 96.94M | 95.22M | 39.96M | 93.77M |
| DilutedEPS | 0.08 | -0.57 | -0.87 | -0.22 |
| BasicEPS | 0.08 | -0.57 | -0.87 | -0.22 |
| DilutedNIAvailtoComStockholders | 8.00M | -54.37M | -34.68M | -20.24M |
| NetIncomeCommonStockholders | 8.00M | -54.37M | -34.68M | -20.24M |
| NetIncome | 8.00M | -54.37M | -34.68M | -20.24M |
| NetIncomeIncludingNoncontrollingInterests | 8.00M | -54.37M | -34.68M | -20.24M |
| NetIncomeContinuousOperations | 8.00M | -54.37M | -34.68M | -20.24M |
| TaxProvision | 288.00K | 0.00 | ||
| PretaxIncome | 8.29M | -54.37M | -34.68M | -20.24M |
| OtherIncomeExpense | 11.37M | 13.15M | 834.00K | -789.00K |
| OtherNonOperatingIncomeExpenses | 11.37M | 13.15M | 974.00K | -789.00K |
| GainOnSaleOfSecurity | -140.00K | |||
| OperatingIncome | -3.08M | -67.52M | -35.52M | -19.45M |
| OperatingExpense | 91.25M | 67.55M | 36.83M | 24.96M |
| ResearchAndDevelopment | 19.58M | 20.27M | 18.38M | 20.27M |
| SellingGeneralAndAdministration | 71.67M | 47.28M | 18.46M | 4.69M |
| GeneralAndAdministrativeExpense | 47.28M | 18.46M | 4.69M | |
| OtherGandA | 47.28M | 18.46M | 4.69M | |
| GrossProfit | 88.17M | 30.00K | ||
| CostOfRevenue | 977.00K | 0.00 | ||
| TotalRevenue | 89.15M | 30.00K | 1.32M | 5.51M |
| OperatingRevenue | 89.15M | 30.00K | 1.32M | 5.51M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 97.95M | 96.41M | 93.94M | 93.77M |
| ShareIssued | 97.95M | 96.41M | 93.94M | 93.77M |
| TotalDebt | 42.00K | 274.00K | 481.00K | 9.03M |
| TangibleBookValue | 249.11M | 230.14M | 272.89M | -31.27M |
| InvestedCapital | 256.80M | 230.76M | 272.89M | -22.86M |
| WorkingCapital | 310.86M | 229.34M | 272.26M | 52.54M |
| NetTangibleAssets | 249.11M | 230.14M | 272.89M | -31.27M |
| CapitalLeaseObligations | 42.00K | 274.00K | 481.00K | 624.00K |
| CommonStockEquity | 256.80M | 230.76M | 272.89M | -31.27M |
| TotalCapitalization | 256.80M | 230.76M | 272.89M | -26.34M |
| TotalEquityGrossMinorityInterest | 256.80M | 230.76M | 272.89M | -31.27M |
| StockholdersEquity | 256.80M | 230.76M | 272.89M | -31.27M |
| GainsLossesNotAffectingRetainedEarnings | 220.00K | 49.00K | 407.00K | 0.00 |
| OtherEquityAdjustments | 220.00K | 49.00K | 407.00K | |
| RetainedEarnings | -123.31M | -131.30M | -76.94M | -42.26M |
| AdditionalPaidInCapital | 379.87M | 362.00M | 349.41M | 10.98M |
| CapitalStock | 10.00K | 10.00K | 9.00K | 3.00K |
| CommonStock | 10.00K | 10.00K | 9.00K | 3.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | |
| TotalLiabilitiesNetMinorityInterest | 94.36M | 2.43M | 8.55M | 92.72M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 70.92M | 37.00K | 3.10M | 84.53M |
| OtherNonCurrentLiabilities | 69.38M | |||
| PreferredSecuritiesOutsideStockEquity | 0.00 | 76.04M | ||
| DerivativeProductLiabilities | 0.00 | 83.00K | ||
| NonCurrentDeferredLiabilities | 1.53M | 0.00 | 2.85M | 3.00M |
| NonCurrentDeferredRevenue | 1.53M | 0.00 | 2.85M | 3.00M |
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 37.00K | 251.00K | 5.41M |
| LongTermCapitalLeaseObligation | 0.00 | 37.00K | 251.00K | 480.00K |
| LongTermDebt | 4.93M | |||
| CurrentLiabilities | 23.44M | 2.39M | 5.44M | 8.19M |
| CurrentDeferredLiabilities | 557.00K | 0.00 | 283.00K | 1.46M |
| CurrentDeferredRevenue | 557.00K | 0.00 | 283.00K | 1.46M |
| CurrentDebtAndCapitalLeaseObligation | 42.00K | 237.00K | 230.00K | 3.62M |
| CurrentCapitalLeaseObligation | 42.00K | 237.00K | 230.00K | 144.00K |
| CurrentDebt | 3.48M | |||
| CurrentNotesPayable | 0.00 | 3.48M | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 2.29M | 315.00K | 447.00K | 660.00K |
| PayablesAndAccruedExpenses | 20.55M | 1.84M | 4.48M | 2.45M |
| CurrentAccruedExpenses | 10.68M | 1.08M | 1.65M | 639.00K |
| Payables | 9.87M | 759.00K | 2.83M | 1.81M |
| OtherPayable | 155.00K | 1.00M | 22.00K | |
| TotalTaxPayable | 4.00K | 174.00K | 0.00 | |
| AccountsPayable | 9.87M | 759.00K | 1.66M | 1.79M |
| TotalAssets | 351.15M | 233.19M | 281.44M | 61.45M |
| TotalNonCurrentAssets | 16.86M | 1.46M | 3.73M | 716.00K |
| OtherNonCurrentAssets | 5.31M | 2.96M | 23.00K | |
| NonCurrentPrepaidAssets | 2.80M | 21.00K | 2.96M | |
| GoodwillAndOtherIntangibleAssets | 7.68M | 617.00K | 0.00 | |
| OtherIntangibleAssets | 7.68M | 617.00K | ||
| NetPPE | 1.07M | 824.00K | 774.00K | 693.00K |
| AccumulatedDepreciation | -200.00K | -121.00K | -48.00K | -14.00K |
| GrossPPE | 1.27M | 945.00K | 822.00K | 707.00K |
| Leases | 24.00K | 24.00K | ||
| OtherProperties | 987.00K | 840.00K | 822.00K | 707.00K |
| MachineryFurnitureEquipment | 255.00K | 81.00K | ||
| Properties | 0.00 | 0.00 | ||
| CurrentAssets | 334.30M | 231.73M | 277.70M | 60.73M |
| OtherCurrentAssets | 1.23M | 652.00K | ||
| PrepaidAssets | 4.67M | 2.03M | 2.31M | 666.00K |
| Inventory | 5.21M | 0.00 | ||
| FinishedGoods | 5.21M | 0.00 | ||
| Receivables | 9.16M | 686.00K | 1.01M | 1.00K |
| OtherReceivables | 109.00K | 213.00K | 1.00K | |
| AccruedInterestReceivable | 987.00K | 686.00K | 796.00K | 1.00K |
| AccountsReceivable | 8.18M | 0.00 | 0.00 | |
| CashCashEquivalentsAndShortTermInvestments | 314.02M | 228.36M | 274.38M | 60.06M |
| OtherShortTermInvestments | 263.20M | 157.39M | 63.86M | 0.00 |
| CashAndCashEquivalents | 50.82M | 70.97M | 210.52M | 60.06M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 12.98M | -59.44M | -40.28M | -17.62M |
| RepaymentOfDebt | 0.00 | -8.68M | -1.82M | |
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 0.00 | 54.81M | ||
| CapitalExpenditure | -563.00K | -175.00K | -199.00K | -55.00K |
| InterestPaidSupplementalData | 0.00 | 366.00K | 576.00K | |
| EndCashPosition | 50.82M | 70.97M | 210.52M | 60.06M |
| BeginningCashPosition | 70.97M | 210.52M | 60.06M | 24.52M |
| ChangesInCash | -20.15M | -139.55M | 150.46M | 35.54M |
| FinancingCashFlow | 72.40M | 6.90M | 190.73M | 53.16M |
| CashFlowFromContinuingFinancingActivities | 72.40M | 6.90M | 190.73M | 53.16M |
| NetOtherFinancingCharges | 69.38M | 198.84M | ||
| ProceedsFromStockOptionExercised | 3.02M | 6.90M | 570.00K | 169.00K |
| NetPreferredStockIssuance | 0.00 | 54.81M | ||
| PreferredStockIssuance | 0.00 | 54.81M | ||
| NetIssuancePaymentsOfDebt | 0.00 | -8.68M | -1.82M | |
| NetLongTermDebtIssuance | 0.00 | -8.68M | -1.82M | |
| LongTermDebtPayments | 0.00 | -8.68M | -1.82M | |
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | -106.10M | -87.18M | -199.00K | -55.00K |
| CashFlowFromContinuingInvestingActivities | -106.10M | -87.18M | -199.00K | -55.00K |
| NetOtherInvestingChanges | -7.50M | |||
| NetInvestmentPurchaseAndSale | -98.04M | -87.00M | 0.00 | |
| SaleOfInvestment | 258.00M | 185.00M | 0.00 | |
| PurchaseOfInvestment | -356.04M | -272.00M | 0.00 | |
| NetPPEPurchaseAndSale | -563.00K | -175.00K | -199.00K | -55.00K |
| PurchaseOfPPE | -563.00K | -175.00K | -199.00K | -55.00K |
| OperatingCashFlow | 13.55M | -59.27M | -40.08M | -17.56M |
| CashFlowFromContinuingOperatingActivities | 13.55M | -59.27M | -40.08M | -17.56M |
| ChangeInWorkingCapital | -1.81M | -7.36M | -12.75M | -356.00K |
| ChangeInOtherWorkingCapital | 2.07M | -3.15M | -1.28M | -2.50M |
| ChangeInOtherCurrentAssets | -21.00K | |||
| ChangeInPayablesAndAccruedExpense | 16.43M | -2.78M | -10.29M | 974.00K |
| ChangeInPrepaidAssets | -6.19M | -1.44M | -1.19M | 1.17M |
| ChangeInInventory | -5.95M | 0.00 | ||
| ChangeInReceivables | -8.18M | 0.00 | ||
| ChangesInAccountReceivables | -8.18M | 0.00 | ||
| OtherNonCashItems | 1.06M | 207.00K | ||
| StockBasedCompensation | 14.53M | 9.23M | 5.84M | 2.83M |
| DepreciationAmortizationDepletion | -7.17M | -6.78M | 319.00K | 213.00K |
| DepreciationAndAmortization | -7.17M | -6.78M | 319.00K | 213.00K |
| AmortizationCashFlow | -7.25M | -6.85M | 285.00K | |
| AmortizationOfIntangibles | -7.25M | -6.85M | 285.00K | |
| Depreciation | 79.00K | 73.00K | 34.00K | 6.00K |
| OperatingGainsLosses | 140.00K | -4.00K | ||
| GainLossOnInvestmentSecurities | 140.00K | -4.00K | ||
| NetIncomeFromContinuingOperations | 8.00M | -54.37M | -34.68M | -20.24M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for SPRY
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|